Throat and rectal swabs may have an important role in MRSA screening of critically ill patients. by Batra, Rahul et al.
Akech, S; Gwer, S; Idro, R; Fegan, G; Eziefula, AC; Newton, CR;
Levin, M; Maitland, K (2007) Volume expansion with albumin com-
pared to gelofusine in children with severe malaria: Results of a con-
trolled trial. Plos Clinical Trials, 1 (5). e21. ISSN 1555-5887
Downloaded from: http://researchonline.lshtm.ac.uk/10032/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
............................................................................................................................................
Volume Expansion with Albumin Compared
to Gelofusine in Children with Severe Malaria:
Results of a Controlled Trial
Samuel Akech1, Samson Gwer1, Richard Idro1, Greg Fegan1,2, Alice C. Eziefula1, Charles R. J. C. Newton1,3,
Michael Levin4, Kathryn Maitland1,4*
1 Kenya Medical Research Institute/Wellcome Trust Research Programme, Centre for Geographic Medicine Research–Coast, Kilifi, Kenya, 2 Infectious
Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Neurosciences Unit, Institute of Child Health,
London, United Kingdom, 4 Department of Paediatrics and Wellcome Trust Centre for Clinical Tropical Medicine, Faculty of Medicine, Imperial College,
London, United Kingdom
Trial Registration: ISRCTN:
35536139
Funding: This study was supported
by a project grant (045194) awarded
by the Wellcome Trust. CRJCN holds
a Wellcome Trust Senior Fellowship
(070114). KM was supported by a
grant from Children of St Mary’s
Intensive Care. The funders played
no part in data collection, analysis, or
presentation of these data.
Competing Interests: The authors
have declared that no competing
interests exist.
Citation: Akech S, Gwer S, Idro R,
Fegan G, Eziefula AC, et al. (2006)
Volume expansion with albumin
compared to Gelofusine in children
with severe malaria: Results of a
controlled trial. PLoS Clin Trials 1(5):
e21. DOI: 10.1371/journal.pctr.
0010021
Received: March 16, 2006
Accepted: July 14, 2006
Published: September 15, 2006
DOI: 10.1371/journal.pctr.0010021
Copyright:  2006 Akech et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: BCS, Blantyre coma
score; CI, confidence interval; ITT,
intention to treat; PP, per protocol
* To whom correspondence should
be addressed. E-mail: kmaitland@
kilifi.kemri-wellcome.org
ABSTRACT
Objectives: Previous studies have shown that in children with severe malaria, resuscitation
with albumin infusion results in a lower mortality than resuscitation with saline infusion.
Whether the apparent benefit of albumin is due solely to its colloidal properties, and thus
might also be achieved with other synthetic colloids, or due to the many other unique
physiological properties of albumin is unknown. As albumin is costly and not readily available
in Africa, examination of more affordable colloids is warranted. In order to inform the design of
definitive phase III trials we compared volume expansion with Gelofusine (succinylated
modified fluid gelatin 4% intravenous infusion) with albumin.
Design: This study was a phase II safety and efficacy study.
Setting: The study was conducted at Kilifi District Hospital, Kenya.
Participants: The participants were children admitted with severe falciparum malaria
(impaired consciousness or deep breathing), metabolic acidosis (base deficit . 8 mmol/l), and
clinical features of shock.
Interventions: The interventions were volume resuscitation with either 4.5% human albumin
solution or Gelofusine.
Outcome Measures: Primary endpoints were the resolution of shock and acidosis; secondary
endpoints were in-hospital mortality and adverse events including neurological sequelae.
Results: A total of 88 children were enrolled: 44 received Gelofusine and 44 received albumin.
There was no significant difference in the resolution of shock or acidosis between the groups.
Whilst no participant developed pulmonary oedema or fluid overload, fatal neurological events
were more common in the group receiving gelatin-based intervention fluids. Mortality was
lower in patients receiving albumin (1/44; 2.3%) than in those treated with Gelofusine (7/44;
16%) by intention to treat (Fisher’s exact test, p ¼ 0.06), or 1/40 (2.5%) and 4/40 (10%),
respectively, for those treated per protocol (p ¼ 0.36). Meta-analysis of published trials to
provide a summary estimate of the effect of albumin on mortality showed a pooled relative risk
of death with albumin administration of 0.19 (95% confidence interval 0.06–0.59; p ¼ 0.004
compared to other fluid boluses).
Conclusions: In children with severe malaria, we have shown a consistent survival benefit of
receiving albumin infusion compared to other resuscitation fluids, despite comparable effects
on the resolution of acidosis and shock. The lack of similar mortality benefit from Gelofusine
suggests that the mechanism may involve a specific neuroprotective effect of albumin, rather
than solely the effect of the administered colloid. Further exploration of the benefits of albumin
is warranted in larger clinical trials...
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INTRODUCTION
Falciparum malaria remains a major cause of morbidity and
mortality in African children, resulting in nearly 1 million
deaths annually [1]. For children presenting to hospital with
severe malaria, in-patient mortality remains high despite
effective antimalarial treatment, especially among those
presenting in coma, most deaths occurring within hours of
admission. Metabolic acidosis, rather than impaired con-
sciousness, has been shown to be the best independent
predictor of death and thus represents an ideal target for a
directed intervention aimed at improving early mortality [2].
In critically ill children, regardless of the underlying causative
disease, the aetiology of metabolic acidosis is most frequently
impaired perfusion [3]. Owing to a lower cardiovascular
reserve relative to adults, shock states develop frequently in
severe illness in children, and are generally treated by volume
expansion, to optimise tissue and organ perfusion [4,5].
Volume resuscitation would therefore seem a logical inter-
vention, in severe malaria, if hypovolaemia were aetiologically
important. However, in most hospitals the use of volume
expansion in children with severe malaria is uncommon, and
may be actively discouraged because of concerns over its
potential to cause pulmonary or cerebral oedema and because
of the lack of deﬁnitive evidence to support its beneﬁt.
Over the past few years we have provided new, clear evidence
that hypovolaemia is common in children with severe malaria
complicated by acidosis [6,7]. Volume expansion would
generally be expected to be beneﬁcial—if the acidosis is due
to volume depletion. Nevertheless, in conditions where the
integrity of the blood–brain barrier is impaired, such as severe
malaria, treatments aimed at correcting volume deﬁcits and
improving tissue perfusion carry the risk of cerebral oedema
[8,9]. We thus reasoned that volume resuscitation with colloids
might be safer than crystalloidal solutions, as the latter freely
equilibrate throughout the extracellular compartment and
thus have the potential risk of accentuating intracranial
pressure [3]. This hypothesis was tested in a previous phase II
randomised controlled trial (see Text S1), which demonstrated
that the resolution of acidosis was similar on either saline or
albumin; however, a secondary analysis showed that albumin
was associated with a signiﬁcantly lower mortality (4%) than
saline (18%), with the greatest beneﬁt amongst those admitted
in coma (5% versus 46%) [10].
Although it could be argued that further exploration of the
optimal treatment regimes for patients with severe malaria
acidosis should focus on albumin, there are reasons for
caution in reaching this conclusion. The vast burden of
childhood death from malaria is borne by the resource-poor
countries of Africa, where provision of albumin as a
resuscitation ﬂuid is complicated by both cost and lack of
availability. We therefore aimed to provide data on the safety
and efﬁcacy of a non-albumin colloid treatment for shock and
correction of acidosis. A secondary objective was to establish
whether a similar survival beneﬁt could be achieved using a
cheaper non-albumin colloidal solution to guide the selection
of resuscitation ﬂuids for inclusion in a phase III trial. Several
types of colloid are available for clinical use—all differ in their
molecular weight, colloid osmotic pressure, half-life in the
intravascular compartment, and side-effect proﬁle, mainly
allergic reactions and adverse effects on coagulation [11,12].
We opted to test one of the modiﬁed gelatins, as these are the
cheapest, most widely available colloid and have been shown
in clinical trials to have a similar efﬁcacy to albumin and other
colloids [13–15]. Here we compare the safety and efﬁcacy of
Gelofusine (a succinylated modiﬁed ﬂuid gelatin 4% intra-
venous infusion) and albumin in children with severe malaria
complicated by metabolic acidosis.
METHODS
Participants
The study was conducted on the paediatric high dependency
unit at the Kenya Medical Research Institute Centre for
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Editorial Commentary
Background: In Africa, children admitted to hospital with severe malaria
are at high risk of death even though effective malaria treatment is
available. Death typically occurs during a narrow time window after
admission and before antimalarial treatments can start working. Acidosis
(excessive acidity of the blood) is thought to predict death, but it is not
clear how acidosis arises. One possibility is that hypovolemia (lowered
blood fluid volume) is important, which would normally require urgent
resuscitation with fluids. However, there is little evidence on what type of
fluid should be given. In the trial reported here, carried out in Kenya’s
Kilifi District Hospital between 2004 and 2006, 88 children admitted with
severe malaria were assigned to receive either albumin solution (a colloid
solution made from blood protein) or Gelofusine (a synthetic colloid). The
primary outcomes that the researchers were interested in were correction
of shock and acidosis in the blood after 8 h. However, the researchers also
looked at death rate in hospital and adverse events after treatment.
What this trial shows: The investigators found no significant differences
in the primary outcomes (correction of shock and acidosis in the blood 8
h after fluids were started) between children given Gelofusine and those
given albumin. However, they did see a difference in death rates
between children given Gelofusine and those given albumin. Death rates
in hospital were lower in the group given albumin, and this was
statistically significant. The researchers then combined the data on death
rates from this trial with data from two other trials with an albumin arm.
This combined analysis also supported the suggestion that death rates
with albumin were lower than with other fluids, either Gelofusine or salt
solution.
Strengths and limitations: There is currently very little evidence from
trials to guide the initial management of fluids in children with severe
malaria. The results from this trial indicate that further research is a
priority. However, the actual findings from this trial must be tested in
larger trials that recruit enough children to establish reliably whether
there is a difference in death rate between albumin treatment and
treatment with other fluids. This trial was not originally planned to find a
clinically relevant difference in death rate, and therefore does not
definitively answer that question. Further trials would also need to use a
random method to assign participants to the different treatments, rather
than alternate blocks (as in this trial). A random method ensures greater
comparability of the two groups in the trial, and reduces the chance of
selection bias (where assignment of patients to different treatments can
be distorted during the enrollment process).
Contribution to the evidence: This study adds data suggesting that
fluid resuscitation with albumin solution, as compared to Gelofusine,
may reduce the chance of death in children with severe malaria.
However, this finding is not definitive and would need to be examined in
further carefully controlled trials. If the finding is supported by further
research, then a solution to the problems of high cost and limited
availability of albumin will need to be found.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
Geographic Medicine Research–Coast, Kiliﬁ District Hospital,
Kenya. Children greater than 3 mo of age presenting with
either of the major clinical features of severe malaria—
impaired consciousness (deﬁned as either prostration or
coma—Blantyre coma score [BCS]  2 [16]) or respiratory
distress—were screened for inclusion in the study. Children
were eligible for inclusion in the trial if they had all of the
following criteria: Plasmodium falciparum parasitaemia, a
clinical feature of severe malaria (as above), metabolic
acidosis with a base deﬁcit greater than 8 mmol/l, a
haemoglobin of greater than 5 g/dl, and a clinical feature of
shock [6]. Informed consent was obtained from all parents or
guardians. Children with any of the following were excluded:
pulmonary oedema (deﬁned clinically as bilateral ﬁne
crepitations in association with sustained hypoxia [oxygen
saturation , 95% measured by a pulse oximeter]), oedema-
tous malnutrition, papilloedema, or refusal of consent.
Ethical approval was granted to enrol children with clinical
features of severe malaria who were critically ill on
presentation (mainly decompensated shock), to start volume
resuscitation without waiting for laboratory results.
Interventions
Volumes administered in this trial were based upon earlier
dose ﬁnding and safety studies [7]. In the earlier randomised
controlled trial, volumes received were based upon the
admission base deﬁcit [10]: those with a base deﬁcit of 8–15
mmol/l (moderate acidosis) received 20 ml/kg, and those with
a base deﬁcit of more than 15 mmol/l (severe acidosis)
received 40 ml/kg. For the current trial we reasoned that to
make patient care relatively independent of blood gas
monitoring, hence the management protocol more general-
isable to resource-poor settings, all children in this trial
would receive an initial bolus of 20 ml/kg (a generic volume
advocated by many paediatric protocols) except for children
who presented with decompensated shock (systolic blood
pressure , 80 mm Hg), who received 40 ml/kg over 1 h. A
further bolus of 20 ml/kg was given to children 1 h later if they
had persistent features of shock [17]. Shock was deﬁned as not
attaining all of the following resuscitation endpoints: heart
rate and systolic blood pressure within threshold range for
age, capillary reﬁll time less than 3 s, and oxygen saturations
greater than 95% in room air. Trial participants were
continuously monitored for blood pressure, oxygen satura-
tions, heart and respiratory rate, and electrocardiography
using a Siemens (Munich, Germany) multi-channel recorder.
Children in coma were also eligible for a double-blind
placebo-controlled trial of fosphenytoin (the FOSCOM study)
given at admission to prevent seizures. The primary endpoint
of the FOSCOM study is post-recovery neurological sequelae.
Projected completion date is the end of 2007. Otherwise, all
other aspects of treatment were identical between the two
groups. Our standard management has been reported
previously [10]. Hyperkalaemia was treated with nebulised
salbutamol and a bolus of glucose (2 ml/kg of 25% dextrose)
after an initial cardioprotective dose of calcium gluconate (1
mmol/kg). Whole blood transfusion (20 ml/kg) given at any
stage during admission was reserved for those whose
haemoglobin fell below 4g/dl, or to less than 5g/dl if associated
with respiratory distress. Ventilation facilities were not
available, but children with short-term apnoea following
convulsions were mask-and-bag ventilated.
On a case-by-case basis adverse events and deaths were
reported to a data safety and monitoring committee and the
Kenyan national ethics research committee. An interim
summary of these events was provided in November 2005.
The trial continued until completion, when 80 children
fulﬁlling all admission criteria had been recruited. The trial
received national ethical approval and was registered in
September 2005 (ISRCTN 35536139) as one of two separate
phase II trials; the second (assessing the safety of the rather
more expensive colloids 6% dextran 70 and 6% hydroethyl
starch) started in June 2006.
Objectives
The study was designed to provide data on the safety and
efﬁcacy of Gelofusine infusion in children with severe malaria
with respect to correction of shock and metabolic acidosis
(primary endpoints) and adverse events including death
(secondary endpoints). The overarching objective was to
provide adequate information to help guide the selection of
albumin, Gelofusine, or both for deﬁnitive multicentre trials.
In order to assess whether the apparent survival beneﬁt of
albumin noted in earlier studies was solely due to colloidal
oncotic properties or whether this effect could be achieved
using a cheaper synthetic colloid, mortality was included as a
secondary endpoint.
Outcomes
Primary outcomes were resolution of shock (measured by
those with shock at 1 h and 8 h) [17] and acidosis (percentage
reduction of base deﬁcit by 8 h). Secondary endpoints
included in-hospital mortality, neurological sequelae at
discharge, and other adverse events including potential
complications of volume resuscitation (pulmonary oedema,
raised intracranial pressure [deﬁned as either a systolic blood
pressure of more than the 90th centile for age in association
with a falling heart rate, or papilloedema, or brain stem
features of transtentorial herniation [18]], or allergic reac-
tion). In phase II trials the use of mortality as an endpoint is
not customary. However, our experience in two previous
trials suggests that the surrogate endpoints (resolution of base
deﬁcit or shock [10] and seizure reduction [19]) did not
predict signiﬁcant differences in mortality. As the children
eligible for this trial represent a high-risk group we therefore
opted to include in-hospital mortality as a secondary
outcome.
Sample Size
Selection of candidate treatments for inclusion in costly and
time-consuming phase III efﬁcacy trials must inevitably be
based on ‘‘an informed guess’’ as to the likelihood of any
treatment proving to be beneﬁcial in the proposed trial. This
study was designed to provide sufﬁcient safety data and some
indication of the likely efﬁcacy of volume expansion with a
cheaper, more widely available colloid, Gelofusine, as
compared with albumin, for which we already had consid-
erable data to suggest a likely beneﬁcial effect. The design of
the current study and the numbers required to address these
objectives were based upon the desire to provide sufﬁcient
data to inform our choice of ﬂuids for inclusion in
multicentre phase III trials, balanced by the necessity to
minimise the exposure of children to a therapeutic inter-
vention for which there is no available data in severe malaria.
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Formal sample sizes were therefore not calculated; we aimed
to recruit 80 children: 40 to receive Gelofusine and 40 to
receive albumin, to achieve our objectives.
Assignment of Interventions
A quasi-randomised design was used, whereby ﬂuid inter-
ventions were allocated sequentially in blocks of ten. In order
to avoid bias due to user preference or patient selection, for
ten consecutive patients only Gelofusine (Braun, Shefﬁeld,
United Kingdom) or 4.5% human albumin solution (Bio
Products Laboratory, Elstree, United Kingdom) were avail-
able on the high dependency research unit for use in the
clinical trial at one time, so the trial clinician had no
discretion and also ensuring that cross-over was not possible.
Otherwise the use of these ﬂuids was strictly monitored, and
they were not available for use outside of the clinical trial.
Eligible children whose parents declined consent received
saline boluses in accordance with local protocol.
Blinding
Owing to the distinctive characteristics of the two study
interventions, the need for rapid volume expansion, and the
potential risk of dosing errors that may result if opaque
administration sets were utilised, the intervention arms were
not masked. Allocation of interventions was also not
concealed.
Statistical Methods
Analysis was performed using Stata version 8 (Stata Corpo-
ration, Texas, United States). The main analysis was by
intention to treat (ITT). A secondary analysis examined only
those complying with the trial protocol (per protocol [PP]
analysis). Baseline and outcome variables were compared
within each study arm using v2 tests for categorical variables
and ANOVA for continuous variables. The primary outcomes
resolution of shock and acidosis were compared by v2 tests
and ANOVA, respectively. A dichotomous variable was
created for shock for each of the time points 0, 1, and 8 h.
A child was designated as in shock at each time point if he had
either hypotension (systolic blood pressure , 80 mm Hg, or
,70 mm Hg if ,1 y) or two or more of the following: severe
tachycardia (.180 beats per minute if ,1 y, .160 if 1–6 y,
and .140 if .7 y), delayed capillary reﬁlling time (3 s), or
oxygen saturations ,95% [17]. The secondary endpoints
death, neurological sequelae in survivors, and potential
adverse effects of colloid resuscitation (pulmonary oedema,
raised intracranial pressure, or allergic reaction) were
compared between the intervention groups using a two-sided
Fisher’s exact test. In addition, we performed a sub-group
analysis comparing mortality in the two intervention arms for
cases presenting in coma (BCS  2), a group with an a priori
increased risk of cerebral oedema, since this was the major
rationale for using albumin. If the beneﬁcial effect of albumin
infusion went beyond its colloid oncotic properties and
therefore reduced the risk of brain swelling, raised intra-
cranial pressure, and ultimately death, then we would expect
to see the greatest differences between the intervention arms
in the coma sub-group. Unadjusted relative risk of death (and
95% conﬁdence interval [CI]) was compared between
albumin and Gelofusine.
As we have used identical criteria for patient enrolment,
treatment, and assessment of outcome in this and previous
phase 1 [7] and 2 [10] studies conducted at Kiliﬁ, we
performed a meta-analysis of the trials to provide a summary
estimate of the effect on mortality of albumin. Data from the
control group (that is, children not receiving volume
resuscitation) of the phase II trial were not included in this
analysis, on the grounds that the control group was not
comparable in terms of a priori risk of fatal outcome, since
the control group included only a relatively low-risk group
with base deﬁcit 8–15 mmol/l (moderate acidosis), whereas
those receiving saline or albumin also included a high-risk
group with base deﬁcit above 15 mmol/l (severe acidosis). We
used summary data for each arm of the trials and employed
standard methodology and the Stata add-in command
‘‘metan’’ to calculate relative risk [20].
RESULTS
Participant Flow
During the study period 94 children were clinically eligible
for trial recruitment; in six cases parental consent was not
granted. Seven cases were assigned as emergencies to receive
study interventions, but were subsequently found not to have
met with all the inclusion criteria (see Figure 1). There were
no protocol deviations and only one protocol violation: a
child allocated to Gelofusine received Haemaccel (another
gelatin-based colloid) in error. The PP analysis includes only
those fulﬁlling all inclusion criteria and adhering to trial
protocol. Compliance with trial protocol was high, and there
were no withdrawals from the study and no losses to follow-
up for in-hospital primary or secondary outcome.
Recruitment
Enrolment began in December 2004 and ended in January
2006, when the projected study sample size had been
accomplished.
Baseline Data
Admission characteristics are summarised in Table 1.
Albumin and Gelofusine groups were well matched with
regard to baseline clinical and biochemical markers of
severity. Up to 60% of the trial participants were in coma
(BCS  2) at admission, an a priori risk factor for poor
prognosis. Although pre-selected by eligibility criteria (im-
paired consciousness or respiratory distress and acidosis), all
children had one or more additional feature of hypovolaemia
including severe tachycardia (heart rate . 160 beats per
minute), delayed capillary reﬁll time (3 s), hypoxia (oxygen
saturations , 95% on pulse oximetry), or hypotension.
Moreover, most fulﬁlled a more stringent international
deﬁnition of shock (hypotension or two of the three features
deﬁning shock). The majority had decompensated metabolic
acidosis with low pH, low bicarbonate, increased base deﬁcit,
and/or a high lactate.
Numbers Analysed
A total of 88 children were included in the ITT analysis (n ¼
44 for albumin and n ¼ 44 for Gelofusine) for primary and
secondary outcomes, including the seven children allocated
to interventions under the emergency consent waiver (see
Figure 1). Eighty children were included in the PP analysis (n
¼ 40 for albumin and n¼ 40 for Gelofusine) that excluded the
seven cases presenting as emergencies (as they did not fulﬁl
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all inclusion criteria) and the child who received Haemaccel
rather than Gelofusine.
Outcomes and Estimation
Primary outcomes. Overall, the resolution of shock and
metabolic acidosis were similar between the groups (Table 2).
By 4 h, all trial participants had attained the level one goals
for resuscitation (data not shown); most (56/78; 72%) had
either no features of shock or only one of the four features
required for further intervention and thus no further ﬂuid
boluses were given after this point. Coma resolution, deﬁned
by the ability to localise a painful stimulus (equivalent to BCS
. 2), occurred more gradually over the ﬁrst 24 h and was
comparable between the groups. By 24 h, 10/39 (26%) of the
albumin group and 7/37 (19%) of the Gelofusine group
remained in coma (p ¼ 0.59).
Secondary outcomes. By ITT analysis, death occurred in 1/44
(2.3%) of the albumin-treated patients compared to 7/44
(15.9%) of the Gelofusine-treated patients (Fisher’s exact test,
p¼ 0.06). Considering only those patients complying with the
protocol, fatal outcome occurred in 1/40 (2.5%) of albumin-
treated children and 4/40 (10%) cases receiving Gelofusine (p
¼ 0.36). In the sub-group admitted in coma, mortality in the
albumin arm was 1/25 (4%) for both ITT and PP analysis and
6/23 (26%; p¼ 0.04) and 3/20 (15%; p¼ 0.31) for ITT and PP
analysis, respectively, in the Gelofusine arm. Neurological
sequelae developed in 3/43 survivors receiving albumin (by
ITT, 7.0%) and in 1/37 survivors receiving Gelofusine (by ITT,
2.7%; Fisher’s exact test, p ¼ 0.62), or 3/39 (7.7%) and 1/36
(2.8%; p¼0.61), respectively, treated PP (see Table 2). All four
cases that developed neurological sequelae presented in coma
Figure 1. Trial Flow
HAS, human albumin solution; ICP, intracranial pressure.
DOI: 10.1371/journal.pctr.0010021.g001
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at admission; three cases had evidence of antecedent neuro-
logical impairment (Table 3). Those with pre-morbid epilepsy
were reported to have increased seizure frequency and
severity 1 mo after discharge.
There was no evidence of pulmonary oedema or ﬂuid
overload in any trial participant; however, fatal neurological
events were more common in the group receiving gelatin-
based intervention ﬂuids (Table 2). Brain swelling and
transtentorial herniation were suspected in two children
assigned to Gelofusine (cases 3 and 4; Table 3). Unilateral
pupillary dilatation was noted at 4 h and 3 h into admission
for cases 3 and 4, respectively; both patients went on to
develop bilateral ﬁxed dilated pupils before having a terminal
respiratory arrest, despite an infusion of mannitol. Two
further deaths in the Gelofusine group (cases 7 and 9) in
addition to the sole albumin fatality (case 11) were associated
with refractory status epilepticus, where optimal seizure
control was compromised by respiratory depression. The
.......................................................................................................................................................................................
Table 1. Baseline Characteristics
Admission Features Sub-Category Albumin Gelofusine p-Value
n 40 40
Median age, months [inter-quartile range] 34 [19–41] 27 [15–39] 0.37
Clinical features, n (%) Coma (BSC  2) 25 (63) 20 (50) 0.52
Deep breathing 35 (88) 30 (75) 0.11
Severe tachycardia (.160 beats per minute) 21 (53) 18 (45) 0.57
Severe tachypnoea (.60 breaths per minute) 10 (25) 12 (30) 0.57
Hypoxia (saturation , 95%) 8 (20) 9 (23) 0.83
Hypotensiona 4 (10) 4 (10) 0.97
Delayed capillary refill (3s) 11 (28) 12 (30) 0.74
Number defined as in shock 35/42 (83) 37/43 (86) 0.77
Status epilepticus 14 (35) 12 (30) 0.63
Posturing 10 (25) 11 (28) 0.53
Hypoglycaemia (,3 mmol/l) 14 (35) 10 (25) 0.37
Weight for age Z-score , 3 11 (28) 9 (23) 0.60
Creatinine . 80 lmol/l 19 (48) 16 (40) 0.97
Lactate . 5 mmol/l 18 (45) 12 (30) 0.30
Potassium . 5 mmol/l 5 (13) 9 (23) 0.18
Laboratory variable, mean 6 standard error Haemoglobin level, mg/dl 81 6 3 83 6 3 0.55
pH 7.22 6 0.02 7.24 6 0.02 0.67
Base deficit, mmol/l 16 6 0.8 16 6 0.8 0.98
Venous PCO2, kPa 3.96 6 0.33 3.68 6 0.27 0.51
Lactate level, mmol/l 6.6 6 0.7 5.6 6 0.7 0.31
Sodium level, mmol/l 134 6 0.9 133 6 1 0.68
Creatinine level, lmol/l 87 6 6 95 6 10 0.50
Potassium level, mmol/l 4.4 6 0.1 4.5 6 0.2 0.70
Bicarbonate level, mmol/l 12.1 6 0.7 11.7 6 0.6 0.65
aSystolic blood pressure , 80 mm Hg if .1 y or ,70 mm Hg if 1 y.
DOI: 10.1371/journal.pctr.0010021.t001..
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Table 2. Major Outcomes
Outcome Type Outcome Sub-Category Albumin Gelofusine p-Value
Primary Resolution of shock over 8 h: number
defined as in shock, n/N (%)
0 h 35/42 (83) 37/43 (86) 0.77
1 h 12/41 (29) 7/37 (19) 0.29
8 h 9/41 (20) 5/37 (14) 0.24
Resolution of acidosis at 8 h: base deficit
reduction, % (95% CI)
Patients with moderate acidosis 35 (12–59) 27 (6–48) 0.59
Patients with severe acidosis 25 (10–40) 21 (9–33) 0.61
Secondary In-hospital death, n/N (%) By ITT 1 (2.3) 7 (16) 0.06
PP 1/40 (2.5) 4/40 (10) 0.36
Neurological sequelae, n/N (%) By ITT 3/43 (7.0) 1/37 (2.7) 0.61
PP 3/39 (7.7) 1/36 (2.8) 0.62
Adverse events, n/N (%) Pulmonary oedema 0 0 —
Raised intracranial pressure 0 2/44 (5) —
Possible allergic reaction 0 1/44 (2.3) —
Others: status at 8 h Volume received as boluses, ml/kg (95% CI) Patients with moderate acidosis 21(18–23) 21(19–24) 0.54
Patients with severe acidosis 27(22–32) 28(23–34) 0.70
Total volume Patients with moderate acidosis 46 (41–51) 44 (40–47) 0.44
Patients with severe acidosis 50 (44–57) 52 (46–58) 0.69
Moderate acidosis defined as base deficit of 8–15 mmol/l. Severe acidosis defined as base deficit of 15 mmol/l or greater.
DOI: 10.1371/journal.pctr.0010021.t002..
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other fatalities were complicated by anaemia and hyper-
kalaemia (two recognised complications of severe malaria)
and wheeze/stridor. For cases complicated by hyperkalaemia,
continuous electrocardiography monitoring did not detect
obvious arrhythmias, and potassium levels fell into the
normal range (see Table 3) except for one case, which
terminated in ventricular tachycardia. Allergic reaction to
Gelofusine was suspected in one case; however, the general-
ised red rash (without adverse cardiovascular effects)
occurred immediately after the initial dose of intravenous
benzylpenicillin, and over 1 h after the bolus of Gelofusine.
Ancillary Analyses
A PubMed search using the terms ‘‘malaria’’ and ‘‘child’’ and
‘‘hypovolaemia’’ and ‘‘therapy’’ found that the two previous
Kiliﬁ-based trials [7,10] and the current trial were the only
ones appropriate to include in a meta-analysis. A further trial
was identiﬁed; however, this was conducted in children with
severe anaemia so was not relevant to this meta-analysis [21].
The meta-analysis showed a pooled relative risk of death with
albumin administration of 0.19 (p ¼ 0.004; 95%CI 0.06–0.59)
compared to saline or Gelofusine ﬂuid boluses (Figure 2).
These trials included 238 eligible children, of whom 112 were
treated with albumin, 86 treated with saline, and 40 treated
with Gelofusine [10]. These three trials have shown a
consistent survival beneﬁt in patients receiving albumin
(Table 4); mortality from the combined data for 112
albumin-treated patients was only 2.6%. This low mortality
on albumin treatment is striking when contrasted with
previously published mortality rates, and with current
unpublished information from other centres (Table 4).
Mortality rates for saline-treated patients (18/%) and Gelo-
fusine-treated patients (16%) are similar to these previous
reports (Table 4). Nevertheless, whilst most of the children
included in these case series did not receive ﬂuid boluses, a
large number may have received a whole blood transfusion (a
form of volume expansion) because of the unscheduled use of
transfusion (for children with haemoglobin . 5 g/dl), which
may in part account for the lower mortality at these sites.
DISCUSSION
Interpretation
These results augment the conclusions of our previous trials,
designed to establish whether hypovolaemia was an impor-
tant complication of severe malaria in African children, to
examine whether volume resuscitation represented a safe and
effective therapeutic intervention [7,10,21], and to establish
whether this could be more safely achieved with albumin or
other colloids than crystalloid. Both Gelofusine and albumin
were found to be equally effective in treating shock and
correcting acidosis uncomplicated by pulmonary oedema or
ﬂuid overload, but fatal neurological complications were
greater in children receiving gelatin-based infusion (4/44; 9%)
than in those receiving albumin (1/44; 2.4%). Even though the
current study was not powered to detect differences in
mortality, our ﬁndings in this trial, like those of our previous
phase I and II studies, suggest that albumin represents a
superior resuscitation ﬂuid in terms of survival, particularly
in cases complicated by coma—a group we hypothesized
would receive the greatest beneﬁt. Mortality in the coma sub-
group receiving Gelofusine (6/23; 26%) was substantially
greater than in those receiving albumin (1/25; 4%). In all
three trials, we were unable to identify a clinical surrogate
marker for outcome, suggesting that further physiological
studies are needed to elucidate the precise mechanism of
.......................................................................................................................................................................................
Table 3. Summary Data on Severe Adverse Events
Case Severe Adverse
Events
Study
Fluid
Outcome Time into
Admission
Action Taken Other Significant
Findings in Patient
1 Drug rash Gelofusine Resolved 2 h Symptomatic management Penicillin allergy
2 Death Gelofusine CRA 3 h Supportive Anaemia and hypotension; no blood
transfusion available
3 Death/drug error Polygelinea RA, fixed dilated pupils 18 h Mannitol 3 three doses Hyperkalaemia at admission, corrected by 4 h,
K ¼ 5.0 mmol/l
4 Death Gelofusine RA, unequal pupils from 3 h 9 h Mannitol 3 two doses Hyperkalaemia at admission, corrected at 4 h,
K ¼ 4.1 mmol/l
5 Epilepsy/
neurosequelae
Gelofusine Ongoing Prolonged stay (7 d) in high
dependency unit
Pre-existing epilepsy
6 Death Gelofusine Refractory stridor/wheeze 7 d Negative HIV test, started
tuberculosis and steroid
therapy on day 3
Malaria, metabolic acidosis, and
respiratory distress at admission,
stridor/wheeze ensued refractory to treatment
7 Death Gelofusine RA 9 h Multiple anticonvulsants Status epilepticus
8 Death Gelofusine Ventricular tachycardia, CRA 4 h Treatment for hyperkalaemia Refractory hyperkalaemia, K ¼ 8.0 mmol/l
(admission) and 7.0 mmol/l (4 h)
9 Death Gelofusine RA 16 h Multiple anticonvulsants Hyperkalaemia corrected at 4 h, K ¼ 4.2
mmol/l; status epilepticus
10 Death Gelofusine CRA 1 h Cardiopulmonary resuscitation Hyperkalaemia at admission; herbal ingestion
11 Death Albumin RA 20 h Multiple anticonvulsants Refractory status epilepticus; initial
hyperkalaemia (for 8 h)
12 Neurosequelae Albumin Ongoing Multiple anticonvulsants Pre-existing epilepsy
13 Epilepsy Albumin Ongoing Multiple anticonvulsants Computed tomography scan: perinatal insult
14 Neurosequelae Albumin Ongoing Multiple anticonvulsants Prolonged coma
aHaemaccel.
CRA, cardiorespiratory arrest; K, potassium; RA, respiratory arrest followed by cardiorespiratory arrest.
DOI: 10.1371/journal.pctr.0010021.t003..
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protection. Neurological sequelae were more common in
survivors receiving albumin in this and our previous trial [10],
but their frequency accords with all other case series of severe
malaria known to us, which have consistently documented
;12% neurological impairment rates in survivors [16,22–25].
Small trials are susceptible to imbalance in admission
characteristics, prognostic markers, and, in trials of volume
expansion, volumes administered. These random ﬂuctuations
may be further exaggerated in an open, non-randomised trial
without concealment of participant allocation to interven-
tions. The albumin and Gelofusine groups were well matched
in terms of baseline and prognostic variables and volumes
received. However, the primary outcome was resolution of
shock, assessed clinically, which may be inﬂuenced by
.......................................................................................................................................................................................
Table 4. Global Summaries of Mortality in Children with Severe Malaria and Acidosis
Type of Report Report Died N Mortality (%) Site Clinical Sub-Group
Cohort studies [40] 7 25 28 Blantyre Coma and acidemia
[41] 14 39 36 Kumasi Lactate . 5 mmol/l
[42] 58 457 13 Papua New Guinea Metabolic acidosis
[43] 5 21 24 Kilifi RD
10 36 28 Impaired consciousness and RD
[44] 15 37 41 Kilifi RD/coma
[6] 40 252 16 Kilifi Acidosis
18 53 34 RD/coma
Personal communicationa 89 548 16 Kumasi RD plus acidosisb
40 93 43 RD/coma plus acidosisb
Personal communicationc 53 306 20 Banjul RDb
Clinical trials [45] 2 18 22 Ghana Lactate . 5 mmol/l
[7] 0 16 0 Kilifi Albumin arm: base deficit . 8 mmol/l
4 25 16 Saline arm: base deficit . 8 mmol/l
[10] 2 56 4 Kilifid Albumin arm: base deficit . 8 mmol/l
11 61 18 Saline arm: base deficit . 8 mmol/l
Current trial 1 40 3 Kilifi Albumin arm: base deficit . 8 mmol/l
4 40 10 Gelofusine arm: base deficit . 8 mmol/l
aTsiri Agbenyega and Jennifer Evans.
bUp to 50% of children received a whole blood transfusion, whereas only ;30% had a haemoglobin less than 5 g/dl (the cut-off point for transfusion recommended by the World
Health Organization).
cChris Olola and Charles Newton on behalf of the Severe Malaria in African Children network.
dThe control arm for this trial is not reported as it only included cases with moderate acidosis (base deficit of 8–14 mmol/l); the mortality was 2/33 (6%). However, 16% of the control
group required rescue therapy volume resuscitation after admission because of the development of life-threatening hypotension.
DOI: 10.1371/journal.pctr.0010021.t004..
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Figure 2. Summary Estimate of the Effect of Albumin on Mortality
A meta-analysis of published trials [7,10] and the current trial comparing the relative risk of death in children with malarial acidosis managed with albumin bolus
versus other fluid boluses (saline or Gelofusine).
DOI: 10.1371/journal.pctr.0010021.g002
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clinician bias or affected by the administration of equal
volumes of intervention ﬂuids whose colloid oncotic proper-
ties may not be equivalent in terms of volume expansion.
Nevertheless, we found that most fatalities in the Gelofusine
arm were neurological in origin, rather than a result of
cardiovascular collapse, which would be more usual if shock
were inadequately corrected. Despite the limitations of the
trial design, our main ﬁnding of a difference in mortality, for
which the major prognostic factor at admission is coma, is less
likely to be affected by our trial design. Indeed, coma was
more common in the albumin group at admission, which is
worthy of consideration when interpreting the study ﬁndings.
Generalisability
Administration of ﬂuid boluses in this trial was based on
bedside assessments of shock that tested the generalisability
of the treatment protocol—since blood gas analysis is not
widely available in Africa. In this regard the protocol was
successful and resulted in a similar mortality beneﬁt in the
albumin arm to that shown in our previous randomised
controlled trial. The striking effect of albumin on mortality is
further evidenced when compared to reports from equivalent
case series. These have consistently documented mortality
rates of 16%–43%, with the greatest mortality occurring in
groups where acidosis or its clinical correlate, deep breathing,
is complicated by coma (Table 3). The beneﬁcial effect of
albumin infusion, beyond that offered by Gelofusine, points
to speciﬁc neuroprotective effects that act through additional
mechanisms other than improving colloid osmotic pressure.
Albumin has a range of physiological effects in addition to
those operating via its colloidal properties [26], which may
result in the amelioration of brain swelling [27,28] and the
improvement of blood ﬂow to critically perfused brain
regions [29]. Albumin exerts direct effects on vascular
endothelium, by binding to the endothelial glycocalyx to
maintain normal permeability [30], and exerts complex
inﬂuences on erythrocyte aggregation by increasing low-
shear viscosity but decreasing erythrocyte sedimentation
under no-ﬂow conditions [31,32]. These non-colloid proper-
ties of albumin are increasingly recognised to be of
therapeutic importance in the treatment of stroke [33] and
may be of particular importance in the pathophysiology of
cerebral malaria, where adherence of parasitised red blood
cells to the endothelium, aggregation of red cells due to the
phenomenon of rosetting, and impaired red cell deform-
ability [34] may be inﬂuenced by the highly negative charge of
the albumin molecule [26].
Overall Evidence
The uncertainty surrounding the use of resuscitation ﬂuids in
children presenting with acute falciparum malaria is of
critical importance from the perspective of health profes-
sionals who are responsible for the emergency management
of children in endemic areas, and needs to be deﬁnitively
addressed in large multicentre trials [35]. The debate over the
merits of volume resuscitation using colloids or crystalloids in
hypovolaemic shock often fails to recognise that distinct
pathophysiological mechanisms are involved in shock in
patients with different underlying diseases, and in children as
compared with adults. Large comparative studies (for
example, [36]) and systematic reviews of them [37] have failed
to identify clear beneﬁts of resuscitation with albumin over
resuscitation with crystalloids in heterogeneous populations
of adults with shock complicated by a wide range of
underlying disorders. However, we believe this should not
preclude consideration of albumin in paediatric trials,
particularly in one involving a single disease entity with a
unique pathophysiology. Although severe malaria has many
features in common with severe sepsis, and hypovolaemia
may be an important contributor to the pathophysiology of
both conditions, there are unique pathophysiological pro-
cesses involved in severe malaria that are clearly distinct from
those occurring in sepsis and in other causes of hypovolaemic
shock. Hypovolaemia, even of only modest degree, would
augment processes, including cytoadhesion of parasitised red
blood cells to vascular endothelium, rosetting, and reduced
red blood cell deformability [2], that lead to a degree of
microvascular obstruction and further compromise organ
perfusion. Albumin may act to improve microvascular
perfusion in malaria through its rheological effects as well
as by volume expansion and inﬂuencing ﬂuid shifts across the
endothelium.
The three studies we have undertaken, including a meta-
analysis, point to a dramatic effect of albumin on the
outcome of severe malaria in children, and a clear beneﬁt
as compared with other ﬂuids, and suggest that further
evaluation of albumin in children with severe malaria, in
large phase III studies, is now needed. The comparable
mortality of Gelofusine treatment with that of saline observed
in our previous studies suggests that inclusion of an
additional synthetic colloid arm is unwarranted, as the
increase trial size necessitated by a four-arm trial (albumin,
saline, Gelofusine, and maintenance-only control) is not
justiﬁed by the small possibility that Gelofusine may be
preferable to saline.
In addition to efﬁcacy and safety, cost and availability of
ﬂuids are important issues. While the roll out of costly
antiretroviral drugs in sub-Saharan Africa has been
justiﬁed on the basis of the scale of the HIV epidemic,
any decision to make albumin widely available would also
require an in-depth cost-effectiveness analysis. Setting aside
the possible effects of albumin on decreasing the length of
hospital stays and reducing the costs and risks to patients
from transfusions, and its potential effect on neurological
sequelae, a ‘‘back of the envelope’’ calculation suggests that
albumin would be highly cost effective, at around US$30–
50 per life saved at current prices. Relevant, but often
overlooked, is the cost of a blood transfusion, estimated at
US$30 in most localities, which is very commonly and
inappropriately prescribed in such cases, despite concerns
about its microbiological safety [38]. Furthermore, if
albumin were shown in future trials to result in signiﬁcant
beneﬁt, then most African countries already have the
infrastructure within large regional transfusion units to
produce a microbiologically safe albumin at low cost if
fairly simple and robust technologies are introduced [39].
Paradoxically, albumin, rather than other synthetic colloids,
would then represent the cheapest and most readily
available colloid. What is currently missing is the scientiﬁc
evidence and imperative to justify introduction of these
technologies. Moreover, improving childhood survival
through the application of evidence-based simple therapies
such as volume resuscitation will have beneﬁts beyond the
www.plosclinicaltrials.org September | 2006 | e210009
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boundaries of severe malaria because of improvements in
childhood survival.
SUPPORTING INFORMATION
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